Stability of equine IgG antivenoms obtained by caprylic acid precipitation: Towards a liquid formulation stable at tropical room temperature

Toxicon

Volumn 53, Issue 6, 2009, Pages 609-615

  Segura, Álvaro ^a   Herrera, María ^a   González, Esteban ^a   Vargas, Mariángela ^a   Solano, Gabriela ^a   Gutiérrez, José María ^a   León, Guillermo ^a  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Antivenom; Caprylic acid; Climatic zone IV; F(ab )2; IgG; Polyols; Sorbitol; Stability

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MANNITOL; OCTANOIC ACID; PHENOL; POLYOL; SORBITOL; VENOM ANTISERUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLIMATE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; FRACTIONATION; HIGH TEMPERATURE; HUMIDITY; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RABBIT; ROOM TEMPERATURE; THERMOSTABILITY; TROPICS; TURBIDITY;

ANIMALS; ANTIVENINS; DRUG STABILITY; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MICE; OCTANOIC ACIDS; PRECIPITATION; PROTEINS; RABBITS; SORBITOL; TEMPERATURE;

EQUIDAE;

EID: 62749130753     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.01.012     Document Type: Article

References (32)

1. Al-Abdulla I., Arnvwa J.M., Rawat S., Smith D.S., Landon J., and Nasidi A. Formulation of a liquid ovine Fab-based antivenom for the treatment of envenomation by the Nigerian carpet viper (Echis ocellatus). Toxicon 42 (2003) 399-404
2. Chapel H.M., Spickett G.P., Ericson D., Engl W., Eibl M.M., and Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J. Clin. Immunol. 20 (2000) 94-100
3. Christensen P.A. The stability of refined antivenin. Toxicon 13 (1975) 75-77
4. 2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. Toxicon 27 (1989) 297-303
5. García M., Monge M., León G., Lizano S., Segura E., Solano G., Rojas G., and Gutiérrez J.M. Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation. Biologicals 30 (2002) 143-151
6. Gené J.A., and Robles A. Determinación de la dosis letal 50% por el método de Spearman-Karber. Revista Médica Hospital Nacional de Niños (Costa Rica) 22 (1987) 25-40
7. Gené J.A., Gómez M., and Cerdas L. Estudio sobre la estabilidad de la actividad neutralizante del suero antiofídico contra veneno de tercipelo (Bothrops asper). Rev. Cost. Cienc. Méd. 7 (1986) 3-5
8. Gutiérrez J.M., Rojas E., Quesada L., León G., Núñez J., Laing G.D., Sasa M., Renjifo J.M., Nasidi A., Warrell D.A., Theakston R.D.G., and Rojas G. Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG: an alternative to the antivenom crisis in Africa. Trans. R. Soc. Trop. Med. Hyg. 99 (2005) 468-475
9. Gutiérrez J.M., Theakston R.D.G., and Warrell D.A. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med. 3 (2006) e150 10.1371/journal.pmed.0030150
10. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products Q5C (1995). www.ich.org/cache/compo/276-254-1.html
11. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Stability Testing of New Drug Substances and Products. Harmonized Tripartite Guideline Q1A (R2) (2003). www.ich.org/cache/compo/276-254-1.html
12. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
13. Lalloo D.G., and Theakston R.D.G. Snake antivenoms. J. Toxicol. - Clin. Toxicol. 41 (2003) 277-290
14. 2 polyvalent antivenoms do not differ in their ability to neutralize hemorrhage, edema and myonecrosis induced by Bothrops asper (Terciopelo) snake venom. Toxicon 35 (1997) 1627-1637
15. Matamoros N., De Gracia J., Hernández F., Pons J., Alvarez A., and Jiménez V. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin. Int. Immunopharmacol. 5 (2005) 619-626
16. Otero R., Gutiérrez J.M., Rojas G., Nuñez V., Díaz A., Miranda E., Uribe A.F., Silva J.F., Ospina J.G., Medina Y., Toro M.F., García M.E., León G., García M., Lizano S., de la Torre J., Márquez J., Mena Y., González N., Arenas L.C., Puzón A., Blanco N., Sierra A., Espinal M.E., Arboleda M., Jiménez J.C., Ramírez P., Díaz M., Guzmán M.C., Barros J., Henao S., Ramírez A., Macea U., and Lozano R. A randomized blind clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops snake bites in Colombia. Correlation between safety and biochemical characteristics of antivenoms. Toxicon 37 (1999) 895-908
17. Otero-Patiño R., Cardoso J.L.C., Dias Da Silva W., Higashi H.G., Nuñez V., Díaz A., Toro M.F., García M.E., Sierra A., García L.F., Moreno A.M., Castañeda N., Silva-Díaz J.F., Murcia M., and Cardenas S.Y. A randomized blinded comparative trial of one pepsin-digested and two whole IgG antivenoms in Bothrops snake bites in Urabá, Colombia. Am. J. Trop. Med. Hyg. 58 (1998) 183-189
18. Raweerith R., and Ratanabanangkoon K. Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography. J. Immunol. Methods 282 (2003) 63-72
19. Rodrigues-Silva R., Martins M.S., Magalhães A., and Santoro M.M. Purification and stability studies of immunoglobulins from Lachesis muta muta antivenom. Toxicon 35 (1997) 1229-1238
20. Rodrigues-Silva R., Antunes G.F.C., Velarde D.T., and Santoro M.M. Thermal stability studies of hyperimmune horse antivenoms. Toxicon 37 (1999) 33-45
21. Rojas G., Espinoza M., Lomonte B., and Gutiérrez J.M. Effect of storage temperature on the stability of the liquid polyvalent antivenom produced in Costa Rica. Toxicon 28 (1990) 101-105
22. Rojas G., Vargas M., Robles A., and Gutiérrez J.M. Turbidity of hyperimmune equine antivenom: the role of phenol and serum lipoproteins. Toxicon 31 (1993) 61-66
23. Rojas G., Jiménez J.M., and Gutiérrez J.M. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 32 (1994) 351-363
24. Schosinsky K., Vargas M., Vinocour G., González O.M., Brilla E., and Gutiérrez A. Manual de Técnicas de Laboratorio (1983), Química Clínica, Universidad de Costa Rica, San José
25. Smalligan R., Cole J., Brito N., Laing G.D., Mertz B.L., Manock S., Maudlin J., Quist B., Holland G., Nelson S., Lalloo D.G., Rivadeneira G., Barragan M.E., Dolley D., Eddleston M., Warrell D.A., and Theakston R.D.G. Crotaline snake bite in the Ecuadorian Amazon: randomized double blind comparative trial of three South American polyspecific antivenoms. Br. Med. J. 329 (2004) 1129-1133
26. Theakston R.D., Warrell D.A., and Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 41 (2003) 541-557
27. United States Pharmacopeia. In vivo Biologic Reactivity Test. USP31/NF26 2008 (2008), United States Pharmaciopeia/Natl. Formulary (Chapter 88)
28. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185 (1999) 129-188
29. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289 (2005) 1-30
30. World Health Organization. Progress in the Characterization of Venoms and Standardization of Antivenoms. WHO Offset Publication No. 58 (1981), World Health Organization, Geneva
31. World Health Organization. Rabies and Envenomings: A Neglected Public Health Issue (2007), World Health Organization, Geneva
32. Zar J.H. Biostatistical Analysis (1999), Prentice-Hall Inc., New Jersey